Ketogenic diets are low in carbohydrates and high in fat, which forces cells to rely more heavily upon mitochondrial oxidation of fatty acids for energy. Relative to normal cells, cancer cells are believed to exist under a condition of chronic mitochondrial oxidative stress that is compensated for by increases in glucose metabolism to generate reducing equivalents. In this study we tested the hypothesis that a ketogenic diet concurrent with radiation and chemotherapy would be clinically tolerable in locally advanced non-small cell lung cancer (NSCLC) and pancreatic cancer and could potentially exploit cancer cell oxidative metabolism to improve therapeutic outcomes. Mice bearing MIA PaCa-2 pancreatic cancer xenografts were fed either a ketogenic diet or standard rodent chow, treated with conventionally fractionated radiation (2 Gy/fraction), and tumor growth rates were assessed daily. Tumors were assessed for immunoreactive 4-hydroxy-2-nonenal-(4HNE)-modfied proteins as a marker of oxidative stress. Based on this and another previously published preclinical study, phase 1 clinical trials in locally advanced NSCLC and pancreatic cancer were initiated, combining standard radiation and chemotherapy with a ketogenic diet for six weeks (NSCLC) or five weeks (pancreatic cancer). The xenograft experiments demonstrated prolonged survival and increased 4HNE-modfied proteins in animals consuming a ketogenic diet combined with radiation compared to radiation alone. In the phase 1 clinical trial, over a period of three years, seven NSCLC patients enrolled in the study. Of these, four were unable to comply with the diet and withdrew, two completed the study and one was withdrawn due to a dose-limiting toxicity. Over the same time period, two pancreatic cancer patients enrolled in the trial. Of these, one completed the study and the other was withdrawn due to a dose-limiting toxicity. The preclinical experiments demonstrate that a ketogenic diet increases radiation sensitivity in a pancreatic cancer xenograft model. However, patients with locally advanced NSCLC and pancreatic cancer receiving concurrent radiotherapy and chemotherapy had suboptimal compliance to the oral ketogenic diet and thus, poor tolerance. Ó 2017 by Radiation
INTRODUCTION
It was predicted that in 2016, an estimated 224,390 new cases of lung cancer and 49,000 new cases of pancreatic cancer would be diagnosed in the U.S. (1) . In 2015, there were an estimated 158,000 and 40,500 deaths due to lung and pancreatic cancer, respectively (2) . The current standard of care for these cancer sites includes a combination of surgery, radiation and chemotherapy. Given the dismal prognosis of both of these cancers, new treatment approaches that selectively enhance tumor cell responses to radiation and chemotherapy are needed. One approach to improve therapeutic outcome is to increase tumor cell metabolic oxidative stress.
Oxidative stress is defined as a disruption in the balance between cellular antioxidants (e.g., glutathione metabolism, thioredoxin metabolism, superoxide dismutase and catalase) and pro-oxidants (e.g., hydrogen peroxide, superoxide, hydroxyl radicals and lipid hydroperoxides), resulting in damage to DNA, proteins and lipid bilayers [ (4) . Furthermore, radiation and chemotherapy induce various levels of oxidative stress causing cell damage (5, 6) . Thus, we hypothesized that dietary reductions in glucose with increasing reliance on the oxidative metabolism of fatty acids would selectively enhance tumor cell versus normal cell responses to standard-of-care radiation and chemotherapy, due to the enhancement in metabolic oxidative stress.
Ketogenic diets are high in fat and low in carbohydrate (7) and are currently used clinically as an alternative therapy for childhood epilepsy (8) . Recently, ketogenic diets have been studied as an adjuvant to cancer therapy in a variety of animal cancer models and in humans (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . We have previously shown that ketogenic diets increase non-small cell lung cancer (NSCLC) radiation and chemoradiation sensitivity in xenograft models via a mechanism that increases cancer cell oxidative stress (9, 11) . In the current study, we extended these observations to a pancreatic cancer xenograft model and then opened two phase 1 clinical trials assessing the tolerability of a ketogenic diet combined with radiation and chemotherapy in locally advanced NSCLC and pancreatic cancer.
METHODS

Tumor Xenografts
MIA PaCa-2 cells (pancreatic cancer cell line) were obtained from the American Type Culture Collection (ATCCt, Gaithersburg, MD). MIA PaCa-2 cells were maintained in Dulbecco's modified Eagle's medium containing 10% FBS (HyClonee Laboratories, Logan, UT). Female 4-6-week-old athymic nu/nu mice were purchased from Harlant Laboratories, Inc. (Indianapolis, IN). Mice were housed in the Animal Care Facility at our institution (University of Iowa), and all procedures were approved by our Institutional Animal Care and Use Committee and conformed to NIH guidelines. Mice were subcutaneously injected with 2.5 3 10 6 MIA PaCa-2 pancreatic cancer cells into the right flanks. When tumors reached approximately 4 mm in diameter, mice were exposed to 12 Gy of radiation (6 fractions of 2 Gy) with or without a ketogenic diet for 25 days as previously described (9) . The 4:1 KetoCalt diet for the animal studies was purchased from Nutricia North America (Gaithersburg, MD) and prepared according to the manufacturer's instructions, while the controls were fed standard mouse chow. Food intake was monitored by daily weighing of the unfinished food pellets. To ensure mice fed with KetoCalt were in ketosis, blood HbA1c was calculated using Mouse Assay Kit (Crystal Chem Inc., Downers Grove, IL) and blood ketone levels were measured with the Precision Xtra Ketone Monitoring System (Abbott, Alameda, CA).
4-Hydroxy-2-Nonenal-(4HNE)-modfied Protein Immunoblotting Assay
4HNE dot blot analysis was performed as previously described elsewhere (9) . Briefly, approximately 20 mg of mouse tumor protein was harvested from each treatment group with protein concentration determined by Lowry Assay. Protein (25 lg) was blotted onto SequiBlote PVDF membrane (Bio-Radt Laboratories Inc., Hercules, CA) and incubated in 250 mM sodium borohydride with 100 mM MOPS, pH 8.0, for 15 min, to chemically reduce the Schiff base adduct and reveal the Michael addition product for antibody recognition. The blot was then incubated with the primary antibody recognizing the Michael addition product of 4HNE-modfied cellular proteins (23) followed by 2 h with a secondary antibody with a horseradish peroxidaseconjugate. Chemiluminescence detection (ECL Plus Western Blotting Detection System, GE Healthcare Bio-Sciences, Pittsburgh, PA) with X-ray film and analysis of integrated densities using ImageJ software (NIH, Bethesda, MD).
Clinical Trials
Investigator-initiated protocols integrating a ketogenic diet into a treatment plan for non-small cell lung cancer (NSCLC) and pancreatic cancer (ketolung and ketopan, respectively) were approved by our Iowa Institutional Review Board (IRB-01) and were listed on clinicaltrials.gov (NCT01419483: ketopan; NCT01419587: ketolung).
Patients The treatment schemas are shown in Fig. 1A and B. Prior to beginning the ketogenic diet, baseline glucose, ketones, BUN, serum, uric acid and fasting whole blood lipid panels were obtained, and participants met with a registered dietitian who collected information about food preferences, determined calorie needs, provided food samplings and discussed dietary procedures. Ketogenic diet meals were designed to provide a 4:1 ratio of fat grams to grams of protein þ carbohydrate (90% of calories from fat, 8% from protein and 2% from carbohydrate). All meals were prepared in the metabolic kitchen at our institution, and foods were weighed to the nearest gram. Nutrient composition was calculated using the USDA Standard Reference Database and manufacturer's data. Breakfast usually consisted of a beverage prepared with 4:1 KetoCalt powder and carbohydrate-free flavorings. Lunches and dinners were composed of conventional foods and recipes modified to be low in carbohydrates. Water and carbohydrate-free beverages were allowed ad libitum and discretionary foods were provided that could be consumed if the participant was hungry. To enhance compliance, menus were individualized for each patient, taking into account their food preferences and any changes in ability to eat as a result of chemo-radiotherapy. Table 4 shows two sample menus. Participants ate lunch at the metabolic kitchen weekdays and took the remaining meals as well as all weekend meals home to eat. Participants kept a daily food checklist to document consumption of food sent home and were queried daily about any foods or beverages consumed that were not part of the meal plan. If participants were unable to consume the entire meal, they were asked to eat a proportional amount of all foods and beverages so as to maintain the 4:1 ratio as closely as possible. Any uneaten food was returned to the metabolic kitchen for weighing and documentation. Participants continued taking their usual dietary supplements during the study. Supplements and medications were checked for carbohydrate content to maintain the 4:1 dietary ratio.
Patients started the ketogenic diet at least two calendar days prior to the beginning of concurrent radiation and chemotherapy. Fingerstick glucose and ketone measurements were obtained prior to the day's radiation treatment in addition to weekly serum ketones and glucose measurements from the in-house clinical pathology laboratory. Fingerstick glucose measurements were obtained using Accu-Chekt Aviva or Aviva Plus (Roche Diagnostics, Indianapolis, IN). Daily ketone measurements were performed on capillary blood samples utilizing a portable and calibrated electrometer (Precision Xtra Blood Glucose and Ketone Monitoring System, Abbott). Weekly ketone values were obtained from venous blood samples utilizing a betahydroxybutyrate (b-HB) assay (Stanbio Laboratory, Boerne, TX) and spectrophotometer (Roche Diagnostics). Participants were assessed weekly with physical examinations and standard-of-care laboratory assessments. A repeat fasting lipid panel was obtained three weeks into radiation treatment. Participants consumed a ketogenic diet for approximately five weeks (pancreatic cancer) to six weeks (NSCLC) while concurrently undergoing chemo-radiotherapy. Pancreatic cancer patients received gemcitabine 600 mg/m 2 weekly and 28 fractions of radiation for a total dose of 50.4 Gy. NSCLC patients received carboplatin AUC ¼ 2 per Calvert formula and paclitaxel 50 mg/m 2 weekly and 33 fractions of radiation for a total dose of 66 Gy. After completion of the combined therapy, participants were followed every three months for one year for adverse events related to therapy.
For the purpose of these studies, adverse events were defined and graded utilizing the Common Terminology Criteria for Adverse Events version 4.0 (27) . Dose-limiting toxicities were adverse events that the research team deemed unacceptable in severity, which occurred during the first five weeks of combined therapy. Identified dose-limiting toxicities included symptomatic grade 2 hypoglycemia, grade 3 hypoglycemia or constipation, and grade 4 diarrhea, nausea or vomiting. Serious adverse events [defined by the FDA Code of Federal Regulations (28) ] with reasonable attribution to ketogenic diet were also considered dose-limiting toxicities. If a participant experienced a dose-limiting toxicity, the ketogenic diet was withheld for up to one calendar week to determine if the adverse event diminished or resolved. Depending on the nature and severity of the event, the ketogenic diet could be resumed to test causality. The treating physician initially determined attribution to the ketogenic diet, and this was then reviewed by the study principal investigators and medical monitor.
These phase 1 clinical trials were designed to assess the safety and tolerability of the ketogenic diet combined with concurrent chemoradiotherapy. Enrollment followed a 3 3 3 study design. If during recruitment, 3 out of 6 participants experienced a dose-limiting toxicity, accrual was stopped and the diet, combined with therapy, was deemed not tolerable and requiring revision. If fewer than three participants experienced a dose-limiting toxicity, the combined therapy would be considered tolerable and investigated in a phase 2 trial powered for efficacy.
Oxidative Stress Biomarker: Protein Carbonyls
Protein carbonyl content in participant plasma was measured according to a protocol adapted from the Protein Carbonyl Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI). Protein carbonyl content is a commonly used marker of general systemic protein oxidation. Briefly, 200 ll of participant plasma from weekly blood draws was mixed with 800 ll of 2,4 dinitrophenylhydrazine to allow protein carbonyls to form a Schiff base and corresponding hydrazone. The amount of protein hydrazone produced was quantified spectrophotometrically at an absorbance of 360-385, and the carbonyl content was standardized to protein concentration. The protein carbonyl content of each subject was normalized to pre-diet levels and a standard curve provided by the manufacturer was used to establish that the samples were in the linear range of the assay. Data were expressed as nmol carbonyl/mg protein.
RESULTS
Ketogenic Diet Enhances Radiation Therapy Response in a Pancreatic Cancer Xenograft Model
Weekly blood tests confirmed mice were in ketosis ( Fig.  2A) . Hemoglobin A1c was significantly lower in mice eating standard mouse chow compared to those on the ketogenic diet (3.9 vs. 4.2, respectively; P , 0.05; Fig. 2B ). Mice treated with the ketogenic diet and radiation survived significantly longer than mice treated with radiation alone (P , 0.05; Fig. 3A ). In addition, mice treated with ketogenic diet and radiation had a slower tumor growth rate than mice treated with radiation alone (P , 0.05; Fig.  3B ). Similar to previously reported studies, the ketogenic diet was well tolerated, given that the mice maintained their weight throughout the diet period and maintained a level of activity similar to mice receiving standard mouse chow (Fig. 3C) (9, 11) . Interestingly, the ketogenic diet also appeared to prevent the weight loss seen in mice treated with radiation and standard chow (Fig. 3C) . These data support the conclusion that 4:1 ketogenic diets enhance radiation response in mouse xenograft models without causing increased toxicity.
Ketogenic Diet Increases Immunoreactive 4HNE-modfied Proteins in Pancreas Xenograft Tumor Tissue
As a marker of in vivo oxidative protein damage caused by lipid peroxidation, immunoreactive 4HNE-modfied protein was analyzed from in tumors harvested from control; ketogenic diet; radiation; and ketogenic diet with radiation treatment groups. Dot blot analysis of tumor samples harvested at the end of two weeks of ketogenic diet and fractionated radiation therapy ( Fig. 4A and B ) demonstrated increased 4HNE-modfied proteins in pancreas xenografts that consumed a ketogenic diet relative to standard mouse chow or IR alone (P , 0.05). These data support the hypothesis that a ketogenic diet increases lipid peroxidation-derived aldehydes that oxidatively damage proteins in tumor tissue.
Patient Characteristics and Treatment Parameters
Patients were screened and enrolled from July 2011 to June 2014. Eleven patients were screened for the ketolung study, with seven enrolling in the trial. Five patients were screened for the ketopan trial, with two enrolling in the trial. The reasons for screen failures included biopsy-proven metastatic disease, self-withdrawal prior to starting therapy and choosing to participate in alternative clinical trials. Participant characteristics of those enrolled are provided in Table 1 .
Participant Experience
On average, participants consuming the ketogenic diet entered ketosis (0.6 mg/dl b-HB) at day 3, with ketones continuing to rise throughout treatment (Fig. 5A-F) . Fingerstick ketone assessment of b-HB (Fig. 5B, D and F) correlated closely with weekly clinical laboratory ketone values (Fig. 5A, C and E) . Both methodologies displayed ketosis at the same time point; however, venous blood sample testing exhibited less variation about separately constructed R 2 regression lines (Fig. 5A-F) . Dietarycompliant participants also showed no consistent reductions in blood glucose levels (Fig. 6A-C) . None of the participants developed ketoacidosis.
Of the seven patients enrolled, two ketolung participants completed the clinical trial. Four ketolung participants discontinued the ketogenic diet during therapy because of difficulty complying with the ketogenic diet, constipation, fatigue, bloating and nausea. One ketolung subject experienced a dose-limiting toxicity (asymptomatic hyperuricemia, grade 4; .10 mg/dl) and was removed from the study. One of the two ketopan participants completed the study. The second ketopan participant experienced a dose-limiting toxicity (dehydration, grade 3) and was removed from the study. Table 2 shows the distribution of graded adverse events. The average weight loss of all ketolung participants was 5.6 kg (6.0% of beginning body weight; grade 1) over the six-week course of radiation and chemotherapy, with the two participants who completed the study losing 8.6 kg and 5.4 kg, respectively (6.2% of pretreatment body weight; grade 1). The ketopan participant who prematurely stopped the ketogenic diet lost 9.4 kg (9.5% of pretreatment body weight; grade 1) over the five-week course of their radiation and chemotherapy while the participant who completed the ketogenic diet lost 6.9 kg (10% of pretreatment body weight) over the course of their radiation and chemotherapy.
Protein carbonyl content is a commonly used general marker for assessing oxidative damage to proteins during biologically relevant stress (24) . Carbonyl content was measured in plasma samples obtained from lung cancer patients Lung-5 and Lung-6, as well as pancreatic cancer patient Panc-1 (successfully completing the diet) along with three weeks from Lung-2 (while this patient was in ketosis, as confirmed by daily fingerstick b-HB). The data in Fig. 7 demonstrate that patients in ketosis during therapy demonstrated significant increases in plasma protein carbonyl content, suggesting that treatment with chemo-radiotherapy and the ketogenic diet resulted in an increase in the steadystate levels of oxidatively damaged proteins.
Participants were followed for long-term outcome ( Table  3 ). The limited number of participants and lack of those who remained compliant with the diet prevented statistical analysis to determine if an oral ketogenic diet was medically tolerable when combined with radiation and chemotherapy. Overall, ketolung participants consumed a ketogenic diet while receiving concurrent radiation and chemotherapy for an average of 16.9 days (range of 0-42 days) of a planned 42 days. Ketopan participants consumed a ketogenic diet for an average of 21 days (range of 8-34 days) of a planned 34 days while receiving concurrent radiation and chemotherapy.
These phase 1 clinical studies were not powered to detect differences in progression-free survival and overall survival. In the ketolung study, the median progression-free survival for those who prematurely stopped consuming the ketogenic diet was 7.5 months (range: 3.2-33 months) while the progression-free survival in the one known subject who completed the ketogenic diet with concurrent radiation and chemotherapy was 4.6 months. The other ketolung subject who completed the ketogenic diet while receiving concurrent radiation and chemotherapy was lost to follow-up but a date of death was established from the public record. After tumor progression was determined, participants went on to receive additional therapies including stereotactic radiosurgery for brain metastasis or different chemotherapy regimens. The median overall survival in the ketolung participants who prematurely stopped consuming the ketogenic diet was 22 months (range: 3.7-33.3 months) while the median overall survival in those who completed the ketogenic diet while receiving concurrent radiation and chemotherapy was 17.7 months (range: 9.4-26 months). Two of five ketolung participants who stopped the ketogenic diet prematurely are still alive (overall survival of 33.3 and 18.4 months) while one of two patients who completed the ketogenic diet is still alive (overall survival of 26 months). The progression-free survival in the ketopan participant who prematurely stopped the ketogenic diet was 5.3 months, with overall survival of 10 months. The ketopan participant who completed the ketogenic diet developed a biliary tract obstruction and sepsis, resulting in death two months after therapy.
DISCUSSION
Despite advances in developing new chemotherapies and radiation targeting techniques, locally advanced NSCLC and pancreatic cancer continue to have a poor prognosis, with median overall survivorship less than 2.5 years (25, 26) . Targeting fundamental differences between cancer and normal cell mitochondrial oxidative metabolism with manipulations such as the ketogenic diet could represent a strategy that can be rapidly implemented for improving outcomes to standard of care radiation and chemotherapy. Fatty acid oxidation occurs primarily in the mitochondria and is dependent on efficient and well-integrated mitochondrial electron transport chain activity. Cancer cell mitochondria are thought to have inefficiencies in mitochondrial electron transport chain activities leading to increased steady-state levels of O 2 -/H 2 O 2 , and they increase glucose metabolism to generate reducing equivalents to compensate for excess H 2 O 2 (3, 4) . From these basic scientific observations, we hypothesized that limiting consumption of glucose and increasing dependence on oxidation of fatty acids during consumption of a ketogenic diet would selectively enhance tumor cell versus normal cell sensitivity to radiation and chemotherapy by a mechanism involving oxidative stress.
The classical ketogenic diet is typically designed to deliver 90% of calories from fat, 8% from protein and 2% from carbohydrate with a 4:1 ratio of fat to combined protein and carbohydrate. We have also previously shown in preclinical NSCLC xenograft models that a ketogenic diet increases radiation and chemotherapy efficacy, which is accompanied by increased tumor levels of a marker for lipid oxidation and protein damage [4HNE-modfied proteins (9)]. In the current study, we extended these observations to show that a ketogenic diet increases sensitivity to radiation in a pancreatic cancer xenograft model. Furthermore, we extended these observations to the initial results of two phase 1 clinical trials assessing the tolerability for a ketogenic diet concurrent with chemo-radiotherapy in locally advanced pancreatic cancer and NSCLC patients.
The phase 1 clinical trial results demonstrate the significant difficulty in achieving dietary compliance that has been encountered in previous studies with adult epilepsy subjects consuming an oral ketogenic diet (29) . In addition, our study was extremely rigorous in ensuring compliance and entry into ketosis, as we were seeking a therapeutic response. In our studies, two out of seven NSCLC patients and one of two pancreatic cancer patients were able to complete the ketogenic diet (;33%) while receiving concurrent chemo-radiotherapy. On average, ketolung study participants were able to consume a ketogenic diet for 16.9 of a planned 42 days while receiving concurrent therapy. Similarly, ketopan study participants were able to consume a ketogenic diet for an average of 21 days out of a planned 34 days while receiving concurrent therapy. Participants met with a registered dietitian and kitchen staff prior to beginning the clinical trial to discuss their food preferences and sample the diet. In addition, participants could modify their food preferences throughout the course of the trial. Efforts were made to include low-carbohydrate versions of milk, bread and desserts as well as modified versions of familiar foods such as cream soups, tacos and pizza. In addition, all meals were provided for participants so they did not have to calculate and prepare their food at home, as has been done in other clinical studies. However, despite having prepared meals and the ability to choose menu options, most participants were unable to consume the ketogenic diet for the duration of their chemo-radiotherapy. The majority of participants, despite expressing their initial motivation for the study, reported difficulty complying with the ketogenic diet while receiving concurrent radiation and chemotherapy for several reasons: the oiliness of the diet; restriction/elimination of carbohydrate-containing foods such as fruits, vegetables, milk, breads and sweets; the substitution of carbohydrate-containing foods with less palatable low-carbohydrate versions; constipation; fatigue; bloating and/or nausea.
When considering our experiences in the context of previous studies in which the ketogenic diet has been used in epilepsy patients the factors contributing to unexpected poor compliance with the diet are multifactorial. First, it is unclear that stringent compliance with daily biochemical verification of ketosis has been attempted with epilepsy patients. Second, most epilepsy patients are children and may demonstrate a better compliance with the diet because they do not have as many preformed dietary preferences and habits as adults. Third, epilepsy patients are not receiving cancer therapy combined with the ketogenic diet. This combination may increase the likelihood of noncompliance because of the toxicities associated with chemotherapy and radiation, which also include loss of appetite, nausea and fatigue. Fourth, the classical ketogenic diet with a 4:1 ratio is very restrictive and requires consumption of a high proportion of fat. Another form of the ketogenic diet, such as 3:1, medium chain triglyceride or modified Atkins, would liberalize dietary intake and may enhance compliance. Regardless of the underlying etiology, it is clear from our limited clinical experience that the current approach was not successful in attaining the verifiable dietary compliance with a high enough percentage of subjects necessary for the continued testing of ketogenic diets in larger trials for pancreatic cancer and NSCLC.
Patients on the ketogenic diet were typically in ketosis after day 3 of the diet. In the ketolung study, one participant experienced hyperuricemia (possibly diet related, grade 4) and two participants developed grade 3 hypokalemia (unlikely related to the diet). In the ketopan study, one participant experienced grade 3 esophagitis (unlikely related to the diet). While these studies were not powered to detect a difference in progression-free survival and overall survival, there was no observed difference in progressionfree survival or overall survival between participants who prematurely discontinued the ketogenic diet and those who consumed the ketogenic diet while receiving concurrent radiation and chemotherapy. These results are consistent with previous reports in glioblastoma subjects (30) .
While there is robust preclinical data in rodents demonstrating that a ketogenic diet is safe and effective, it has been shown that adherence to the diet is difficult for adult human subjects. In a pilot trial examining 16 subjects with advanced disease and no further established therapeutic options, participants were offered a low-carbohydrate, highfat diet of no more than 70 g of carbohydrates. Even with these less stringent carbohydrate requirements, only 5 of 16 patients completed the study, with 3 patients reaching stable ketonuria of greater than 0.5 mmol/l (17) . Similar to our study, subjects on this previous trial reported mild constipation, nausea, fatigue, as well as significant weight loss of 2 kg. The relatively small weight loss in this study may be attributed to the fact that patients were not undergoing concurrent chemo-radiotherapy.
In another retrospective study examining the safety of a ketogenic diet during concurrent chemo-radiotherapy for glioblastoma multiforme, six patients who consumed a ketogenic diet tolerated the diet well and had no grade 3 toxicity, demonstrating the potential for the ketogenic diet's safety profile (30) (31) (32) . Patients in this study also reported weight loss, and interestingly, had significant reductions in their serum glucose level on the diet despite concurrent treatment with high-dose steroids. In the ERGO trial, in which ketogenic diets were studied in recurrent glioblastoma cases, the authors reported a higher compliance rate to the diet, with 12 out of 17 patients completing the trial (30) . However, ketosis was only confirmed weekly by urine ketones at greater than 0.5 mmol/l. In addition, in this trial ketosis was not maintained in 5/12 patients, since their urine was positive for ketones less than 60% of the time, indicating a possible difficulty with adherence to the ketogenic diet.
Overall, the current study continues to support the hypothesis that ketogenic diets are capable of increasing tumor responses to radiation in rodent xenograft models. Our studies in humans also continue to demonstrate the difficulty for adults to comply with a ketogenic diet while receiving concurrent radiation and chemotherapy in locally advanced NSCLC and pancreatic cancer. One possible solution to difficulties with ketogenic diet compliance is to deliver the ketogenic diet in a clinical setting where PEG tube usage is high during therapy. To test this hypothesis additional studies assessing the delivery of a ketogenic diet via PEG tube in head and neck cancer patients are ongoing (ClinicalTrials.gov identifier: NCT01975766). Lung and pancreatic cancer patients on a 4:1 ketogenic diet have significantly higher plasma protein carbonyl content compared to their baseline pre-diet value. Blood from patients with lung cancer (Lung-2, Lung-5 and Lung-6) and pancreatic cancer (Panc-1) were drawn weekly and the carbonyl content was measured in plasma and normalized to pre-diet levels. Patients were in confirmed ketosis, and data points represent weekly values. *P , 0.05 with unpaired t test.
